AstraZeneca PLC (NASDAQ:AZN) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET

Company Participants

Andy Barnett - Head, Investor Relations
Pascal Soriot - Executive Director and CEO
Aradhana Sarin - Executive Director and CFO
Dave Fredrickson - Executive Vice President, Oncology Business
Susan Galbraith - Executive Vice President, Oncology Research and Development
Ruud Dobber - Executive Vice President and President, BioPharmaceuticals
Sharon Barr - Executive Vice President, BioPharmaceuticals Research and Development
Marc Dunoyer - Chief Executive Officer, Alexion and CSO, AstraZeneca

Conference Call Participants

James Gordon - JPMorgan
Richard Parkes - BNP Paribas Exane
Sachin Jain - Bank of America
Christopher Uhde - SEB
Gonzalo Artiach - Danske Bank
Steve Scala - Cowen
Rajan Sharma - Goldman Sachs
Etzer Darout - BMO
Simon Baker - Redburn
Emmanuel Papadakis - Deutsche Bank
Mattias Haggblom - Handelsbanken
Eric Le Berrigaud - Stifel
Rajesh Kumar - HSBC
Gonzalo Artiach - Danske Bank
Peter Welford - Jefferies
Luisa Hector - Berenberg Capital Markets
Emily Field - Barclays

Operator

Good morning to those joining from the U.S., good afternoon to those in the U.K. and Central Europe, and good evening to those listening in Asia. Welcome ladies and gentlemen to AstraZeneca’s Nine Months and Q3 Results 2024 Webinar for Investors and Analysts.

Before I hand over to AstraZeneca, I’d like to read the Safe Harbor statement. The company intends to utilize the Safe Harbor provisions of the United States Private Securities Litigation Reform Act of 1995.

Participants on this call may make forward-looking statements with respect to the operations and financial performance of AstraZeneca. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements.

Any forward-looking statements made on this call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking statements. Please also carefully review the forward-looking statements disclaimer in the slide deck that accompanies this presentation.

There will be an opportunity to ask questions after today’s presentation. Please use the raise a hand feature to indicate you wish to ask a question at any time and remember to unmute your line when invited to speak. You can also submit a written question using the Q&A tab on your screen.